Eye-tracking attentional therapy to reduce PTSD symptoms
Official title: Evaluation of the Effectiveness of Eye-tracking Assisted Attentional Bias Reduction Therapy on Reducing Symptoms of Post-traumatic Stress Disorder
Run by University Hospital, Lille · NCT05331534 · Data updated 2026-11-12
This trial tests whether adding eye-tracking to attention-control training can reduce PTSD symptoms in French-speaking adults with PTSD.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 60 Years |
| Sex | All |
| Enrollment | 140 (estimated) |
| Sponsor | University Hospital, Lille Academic / other |
| Locations | 1 site (Lille) |
| Status | Recruiting |
| Started | February 2, 2024 |
| Main results expected | February 2, 2028 |
| Study ends | February 2, 2029 |
| Registry record updated | August 24, 2025 |
| Trial ID | NCT05331534 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults who meet DSM-5 criteria for PTSD, speak French, have normal or corrected vision and hearing, hold health insurance, and can give informed consent are the intended participants.
✕Probably not a fit
People who are pregnant or breastfeeding, have neurological disorders, active substance use (other than tobacco/alcohol), significant psychiatric comorbidity, sensory impairments, or who cannot attend sessions in Lille are unlikely to be eligible or to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The protocol compares an eye-tracking–assisted attention control training that specifically targets sustained attention to negative stimuli with a standard attention control training in adults meeting DSM-5 PTSD criteria. Participants are screened with CAPS and PCL-5 and must have normal or corrected vision and hearing and be able to consent in French. The eye-tracking version provides real-time measurement and feedback to interrupt pathological sustained attention to negative images, while the control uses conventional attention tasks without eye-tracking. Symptom measures and eye-tracking attention metrics are collected before and after the intervention to determine whether the targeted approach leads to greater symptom reduction.
Why it matters
Potential benefit: If successful, this could provide a non-drug therapy that reduces PTSD symptoms by retraining attention away from negative stimuli.
How similar studies have gone: Previous attention-bias modification studies have shown mixed results, while eye-tracking–assisted targeting of sustained bias is relatively novel with some preliminary promising data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Understanding and able to express themselves in French * Giving informed consent, by dating and signing the study participation form * Having health insurance coverage * Normal or corrected to normal vision and hearing * DSM-5 PTSD criteria, assessed using the CAPS and PCL-5 Exclusion Criteria: * Minors or adults under guardianship, under judicial protection, persons deprived of liberty * Pregnant or breastfeeding women * Refusal to participate after being clearly and fairly informed about the study * Sensory, visual or auditory incapacity to participate in the study * Personal history of neurological disorder or current neurological disorder * Use of drugs other than tobacco and alcohol * Alcohol use on the day of experimentation * Personal history of psychiatric disorders or current psychiatric disorders other than anxiety, depressive, or trauma and stress disorders assessed at clinical interview and with MINI * Personal history of multiple trauma in childhood * Psychotropic medication treatment not stabilized over the past 4 weeks * MOCA \< 26 * Contraindication to prolonged exposure therapy
Where it's running
-
Hôpital Fontan 2
Lille, France Recruiting
Study contacts
- Principal investigator: Guillaume Vaiva, MD,PhD — University Hospital, Lille
- Study coordinator: Guillaume VAIVA, MD,PhD
- Email: guillaume.vaiva@chru-lille.fr
- Phone: 0320445962
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Anger, Social Thinking, and PTSD in French Veterans
This study tests whether PTSD in former French military personnel is linked to higher anger through changes in social thinking abilities.
-
TSND-201 treatment for PTSD in adults
This study tests two doses of TSND-201 or placebo to see if it helps adults with PTSD.
-
Long-term outcomes after Hyperbaric Oxygen Therapy in veterans with TBI, PCS, or PTSD
This study tests whether benefits from HBOT persist over time for veterans with brain injury or related conditions.
-
SEE FAR CBT for Adults With PTSD
This 12-week, one-on-one SEE FAR CBT program tests a trauma-focused therapy to see if PTSD symptoms improve in adults 18 and older.
-
Brief SEE FAR CBT: a short, focused therapy for adults with PTSD
A 6-session Brief SEE FAR CBT treatment is tested against usual dynamic psychotherapy for adults with PTSD to see if it reduces symptoms.
-
MDMA Therapy for PTSD in Veterans
This phase 2 study tests a fixed 120 mg dose of MDMA, followed by a 60 mg supplemental dose, plus therapy, to see if it helps adults who are veterans with PTSD.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.